Sensei Biotherapeutics (SNSE) grants PFO 80,000 stock options

Rhea-AI Filing Summary

Sensei Biotherapeutics’ principal financial and accounting officer, Josiah Craver, received a grant of stock options covering 80,000 shares of common stock on April 10, 2026. The options have an exercise price of $29.89 per share and expire on April 9, 2036.

According to the vesting terms, 25% of the shares subject to the option vest and become exercisable on April 10, 2027, with the remaining shares vesting in 36 equal monthly installments so that the award is fully vested by April 10, 2030, subject to his continuous service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Craver Josiah

Role PFO & PAO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	80,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 80,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 80,000 options Exercise price: $29.89 per share Underlying shares: 80,000 shares +4 more

7 metrics

Option grant size 80,000 options Stock Option (right to buy) granted April 10, 2026

Exercise price $29.89 per share Conversion or exercise price of stock option

Underlying shares 80,000 shares Underlying common stock for the option grant

Post-transaction derivative holdings 80,000 options Total derivative securities following this transaction

Initial vesting date April 10, 2027 25% of option shares vest and become exercisable

Full vesting date April 10, 2030 Option fully vested on fourth anniversary of grant

Expiration date April 9, 2036 Option expiration if not exercised

Key Terms

Stock Option (right to buy), exercise price, vest and become exercisable, equal monthly installments, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 29.8900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"25% of the shares subject to the option vest and become exercisable on April 10, 2027"

equal monthly installments financial

"remaining shares vest and become exercisable in 36 equal monthly installments thereafter"

continuous service financial

"subject to the Reporting Person's continuous service with the Issuer as of each such vesting date"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Craver Josiah

(Last) (First) (Middle)

C/O SENSEI BIOTHERAPEUTICS, INC.

1405 RESEARCH BLVD, SUITE 125

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PFO & PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$29.89	04/10/2026		A		80,000		(1)	04/09/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the date of grant, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Josiah Craver	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SNSE report for Josiah Craver on this Form 4?

Sensei Biotherapeutics reported that Josiah Craver received a grant of stock options for 80,000 shares of common stock. These options were awarded on April 10, 2026 and represent a compensation-related acquisition, not an open-market purchase or sale of existing shares.

What is the exercise price and size of Josiah Craver’s SNSE stock option grant?

The stock option grant to Josiah Craver covers 80,000 shares of Sensei Biotherapeutics common stock at an exercise price of $29.89 per share. This means he can later buy shares at $29.89, regardless of the market price, once the options have vested and are exercisable.

How do the SNSE stock options granted to Josiah Craver vest over time?

Twenty-five percent of the shares subject to the option vest and become exercisable on April 10, 2027. The remaining shares vest in 36 equal monthly installments after that date, so the entire 80,000-share option becomes fully vested by April 10, 2030, assuming continuous service.

When do Josiah Craver’s SNSE stock options expire if not exercised?

The stock options granted to Josiah Craver expire on April 9, 2036 if not exercised. After that expiration date, any unexercised portion of the 80,000-share option grant will no longer be exercisable, even if it had fully vested before expiration.

Is Josiah Craver’s Form 4 transaction in SNSE shares a market buy or sell?

The Form 4 transaction is a grant of derivative securities, not a market trade. It reports an acquisition of stock options for 80,000 underlying shares as compensation, with no open-market buying or selling of Sensei Biotherapeutics common stock disclosed in this particular filing.